DATASET RE-READ 2026-11-2042 PROGRAMSNEXLIFE PRICES READ 2026-11-20EVERY FIGURE CARRIES ITS READ DATE
TopGLP1Providers.comverified price index
DATED PRICES

Source-verified

This database’s highest evidence status: the figure was read on the provider’s own published pricing page at the capture date and archived. The contrast classes — stated-not-verified, third-party-reported, no-price-published — are labeled on every record, because a ranking is only as honest as its worst-sourced number.

Released · Last reviewed · how we verify

Where the term bites in the current data: our dated tirzepatide reads run $129–$399/month all-in and semaglutide $99–$299 (newest reads; NexLife November 20, 2026), and nearly every dollar of those spreads is explained by the vocabulary on this glossary’s pages — memberships inside or outside headline figures, flat versus tiered ladders, prepaid terms dressed as monthly prices, evidence flags separating captures from claims. Reading this market is mostly a matter of knowing which of those words applies to the number in front of you.

It is the difference between the 17 programs the rankings will sort and the records they will only display. Related figures live on the pages this term links to, and every one of them regenerates from the same dataset this definition does.

See the term in action across the price database and the methodology.

All-in priceMaintenance-dose basisDose-flat pricingDose-tiered pricingMembership feePrepaid term

Primary sources

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.